Changing what’s possible
for People living with T cell-driven autoimmune disease
DELIVERING siRNA, ONLY TO T CELLS
Selective delivery of siRNA to T cells enables modulation of the specific T cell sub-types that drive disease pathology with sequence-level specificity and greater pharmacologic control.
siRNA delivery to T cells has historically been limited by the inability to selectively target T cells, while maintaining efficient release of siRNA into the cytoplasm.
Delivering siRNA with our T cell specific cell-targeted lipid nanoparticle (ctLNP) could silence disease-driving genes in T cells with genetic precision, potently blocking their function while sparing the broader immune system.
THE POWER OF CHANGING T CELL BEHAVIOR IN VIVO
T cells are master regulators of the immune system, and they are at the heart of tissue damage in a number of autoimmune diseases. Autoreactive T cells have a role in breaking tolerance and directly drive inflammation and tissue destruction.
By changing the activity of T cells, our targets can change how T cells activate, differentiate, migrate, and damage tissues.
Using our redosable ctLNP delivery system to selectively target T cells in vivo may open a broad indication space of T cell driven autoimmune diseases.
OUR UNIQUE DELIVERY UNLOCKS THE POTENTIAL FOR siRNA THERAPEUTICS IN T CELLS
T cell siRNA therapeutics require receptor-selective targeting and endosomal escape – our unique ctLNP delivery technology accomplishes both for the first time and unlocks a powerful modality for T cells.
Our lead ctLNP targets systemic T cells and has been engineered to drive efficient delivery across CD8+ and CD4+ effector T cell subsets.
Leadership Team
Board of Directors
Scientific Advisory Board
News
Keep up to date with our latest news.
Join Us
We are always looking for those who are ready to share their vision, talent, and tenacity—who believe in our mission and themselves.